DT en Español could receive a commission if you buy a product from the site
Pfizer’s vaccine partially protects against the omicron variant of SARS-CoV-2, according to early research results from the Durban-based African Health Research Institute.
According to the scientists (the same ones who first reported the presence of this worrisome variant of the virus), omicron is capable of evading the immunity induced by the administration of the P vaccinefizer better than other variants.
Specifically, according to the study omicron is capable of reducing antibodies up to 40 times generated by the American pharmaceutical vaccine. For the study, several subjects received two doses of the Pfizer-BioNTech vaccine. When studying their blood plasma, it was observed that before omicron they lost 41 times their levels of blocking antibodies to the virus compared to the strain that was circulating at the beginning of the pandemic.
The loss of immune protection is “solid, but not complete,” he explained to Bloomberg Alex Sigal, head of research in the laboratory in charge of the study.
On the other hand, a separate study from the Karolinska Institute in Stockholm was more optimistic. In it, it was glimpsed that, although there is a loss of antibodies to omicron, the decline is much worse than to the delta variant, the strain that currently causes the majority of COVID-19 cases worldwide. This study also concludes that the inoculation of a new booster dose against the new variant will be necessary.
These results offer an early glimpse of the potential damage that omicron spread could cause, but they are not yet conclusive, so this information should be viewed with caution.